These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34973307)

  • 1. Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists.
    Stavnsbjerg C; Christensen E; Münter R; Henriksen JR; Fach M; Parhamifar L; Christensen C; Kjaer A; Hansen AE; Andresen TL
    J Control Release; 2022 Feb; 342():337-344. PubMed ID: 34973307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.
    Subasic CN; Butcher NJ; Minchin RF; Kaminskas LM
    Mol Pharm; 2023 Jul; 20(7):3494-3504. PubMed ID: 37256791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.
    Gaballa SA; Shimizu T; Takata H; Ando H; Ibrahim M; Emam SE; Amorim Matsuo NC; Kim Y; Naguib YW; Mady FM; Khaled KA; Ishida T
    Mol Pharm; 2024 Feb; 21(2):622-632. PubMed ID: 38273445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route.
    Takata H; Shimizu T; Yamade R; Elsadek NE; Emam SE; Ando H; Ishima Y; Ishida T
    J Control Release; 2023 Aug; 360():285-292. PubMed ID: 37355210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.
    El Sayed MM; Shimizu T; Abu Lila AS; Elsadek NE; Emam SE; Alaaeldin E; Kamal A; Sarhan HA; Ando H; Ishima Y; Ishida T
    Int J Pharm; 2022 Mar; 615():121539. PubMed ID: 35124114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
    Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
    Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein.
    Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T
    Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients.
    Miao G; He Y; Lai K; Zhao Y; He P; Tan G; Wang X
    J Control Release; 2023 Nov; 363():12-26. PubMed ID: 37717659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon.
    El Sayed MM; Takata H; Shimizu T; Kawaguchi Y; Abu Lila AS; Elsadek NE; Alaaeldin E; Ishima Y; Ando H; Kamal A; Sarhan HA; Ishida T
    J Control Release; 2020 Jul; 323():102-109. PubMed ID: 32278827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells.
    Shimizu T; Mima Y; Hashimoto Y; Ukawa M; Ando H; Kiwada H; Ishida T
    Immunobiology; 2015 Oct; 220(10):1151-60. PubMed ID: 26095176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance.
    Kaminskas LM; McLeod VM; Porter CJ; Boyd BJ
    J Pharm Sci; 2011 Nov; 100(11):5069-77. PubMed ID: 21721002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture.
    Lin YC; Chen BM; Tran TTM; Chang TC; Al-Qaisi TS; Roffler SR
    J Control Release; 2023 Feb; 354():354-367. PubMed ID: 36641121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions.
    Kozma GT; Mészáros T; Vashegyi I; Fülöp T; Örfi E; Dézsi L; Rosivall L; Bavli Y; Urbanics R; Mollnes TE; Barenholz Y; Szebeni J
    ACS Nano; 2019 Aug; 13(8):9315-9324. PubMed ID: 31348638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response.
    Shimizu T; Ichihara M; Yoshioka Y; Ishida T; Nakagawa S; Kiwada H
    Biol Pharm Bull; 2012; 35(8):1336-42. PubMed ID: 22863934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.
    Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H
    Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
    Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
    Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
    Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
    Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy.
    Yang Q; Ma Y; Zhao Y; She Z; Wang L; Li J; Wang C; Deng Y
    Int J Nanomedicine; 2013; 8():1257-68. PubMed ID: 23576868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
    Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
    Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes.
    Talkington AM; McSweeney MD; Wessler T; Rath MK; Li Z; Zhang T; Yuan H; Frank JE; Forest MG; Cao Y; Lai SK
    J Control Release; 2022 Mar; 343():518-527. PubMed ID: 35066099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.